ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is labeled with high mortality and tolerance to chemotherapy. Sorafenib has been the first‐line treatment option in HCC patients for past decades, while the therapeutic effect was limited in almost HCC patients. METHODS: In this study, we analyzed public om...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ying, Shang, Jin, Li, Yan, Zhong, Deyuan, Zhang, Zilong, Yang, Qinyan, Lai, Chunyou, Feng, Tianhang, Yao, Yutong, Huang, Xiaolun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939139/
https://www.ncbi.nlm.nih.gov/pubmed/35946175
http://dx.doi.org/10.1002/cam4.5110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939139/
https://www.ncbi.nlm.nih.gov/pubmed/35946175
http://dx.doi.org/10.1002/cam4.5110

Ejemplares similares